San
Diego, CA, USA -- Global
Cancer Technology, Inc. announced today that the
company has signed a Licensing Agreement with the University of
California San Diego to bring to market a drug delivery platform that
links a nanocrystal to a prodrug that can be activated using
radiosurgery.
"This
represents the first ever effort to utilize radiosurgery to activate
a prodrug linked to a nanocrystal scintillator" said Mr. John
Clark, Chairman and CEO of Global Cancer Technology, Inc. "The
process allows a drug to be delivered to a tumor site and
radiosurgically activated releasing 100% of the drug's energy
directly at the tumor site". Mr. Clark went on to say that
"aside from its use in fighting cancer, this delivery platform
when activated by exceedingly low, regionally focused doses of
radiation can provide tremendous benefits in infectious disease drug
treatments in terms of selectivity, dosing, and tolerability".
Drs.
Milan Makale, Wolf Wrasidlo and Santosh Kesari, principal inventors
of the patented process jointly commented, "The University is
very pleased to be moving this transformative technology forward and
working with Global Cancer Technology, Inc. in the commercialization
process". They added "UC San Diego is excited about the
prospect of advancing cancer and infectious disease drug delivery
improvements for patients and the medical community".
Global
Cancer Technology, Inc. provides PRODUCTS, PARTNERSHIPS and SERVICES
to the worldwide medical and oncology market.
Media
Contact:
Kelly
O'Connor
Global
Cancer Technology, Inc.
Ph:
(619) 818-2411
Fax:
(800) 886-3880
